JPH0136819B2 - - Google Patents
Info
- Publication number
- JPH0136819B2 JPH0136819B2 JP57226685A JP22668582A JPH0136819B2 JP H0136819 B2 JPH0136819 B2 JP H0136819B2 JP 57226685 A JP57226685 A JP 57226685A JP 22668582 A JP22668582 A JP 22668582A JP H0136819 B2 JPH0136819 B2 JP H0136819B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- group represented
- bistrifluoromethylphenyl
- aminocarbonyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000001875 compounds Chemical class 0.000 claims description 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 7
- 206010010904 Convulsion Diseases 0.000 claims description 6
- 230000036461 convulsion Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- -1 carboximide compound Chemical class 0.000 description 43
- 238000002844 melting Methods 0.000 description 18
- 230000008018 melting Effects 0.000 description 18
- 238000000921 elemental analysis Methods 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000000034 method Methods 0.000 description 10
- 230000000704 physical effect Effects 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- CDIDGWDGQGVCIB-UHFFFAOYSA-N 3,5-bis(trifluoromethyl)aniline Chemical compound NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CDIDGWDGQGVCIB-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- SPUOPTCIVFNKFX-NWDGAFQWSA-N (1r,2s)-2-[[3,5-bis(trifluoromethyl)phenyl]carbamoyl]cyclohexane-1-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCC[C@@H]1C(=O)NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 SPUOPTCIVFNKFX-NWDGAFQWSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 206010019196 Head injury Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 239000000924 antiasthmatic agent Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 206010015037 epilepsy Diseases 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 235000011121 sodium hydroxide Nutrition 0.000 description 4
- KOODXLCUAZRPCI-UHFFFAOYSA-N 2-[[3,5-bis(trifluoromethyl)phenyl]carbamoyl]cyclohexene-1-carboxylic acid Chemical compound C1CCCC(C(=O)O)=C1C(=O)NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 KOODXLCUAZRPCI-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000016285 Movement disease Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 229940127226 anticholesterol agent Drugs 0.000 description 3
- 239000003699 antiulcer agent Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000001665 lethal effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- SPUOPTCIVFNKFX-VXGBXAGGSA-N (1r,2r)-2-[[3,5-bis(trifluoromethyl)phenyl]carbamoyl]cyclohexane-1-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCC[C@H]1C(=O)NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 SPUOPTCIVFNKFX-VXGBXAGGSA-N 0.000 description 2
- KFJCLBNTNXRHIN-TXEJJXNPSA-N (3as,7ar)-2-[3,5-bis(trifluoromethyl)phenyl]-3a,4,5,6,7,7a-hexahydroisoindole-1,3-dione Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(N2C([C@@H]3CCCC[C@@H]3C2=O)=O)=C1 KFJCLBNTNXRHIN-TXEJJXNPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000022540 Consciousness disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000003627 anti-cholesterol Effects 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 150000001244 carboxylic acid anhydrides Chemical class 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- PWEKCCPUQNOPFO-UHFFFAOYSA-N 2-oxaspiro[3.3]heptane-1,3-dione Chemical compound O=C1OC(=O)C11CCC1 PWEKCCPUQNOPFO-UHFFFAOYSA-N 0.000 description 1
- QUGUPCGKQWUAPF-UHFFFAOYSA-N 2-oxaspiro[3.5]non-6-ene-1,3-dione Chemical compound O=C1OC(=O)C11CC=CCC1 QUGUPCGKQWUAPF-UHFFFAOYSA-N 0.000 description 1
- QTDXSEZXAPHVBI-UHFFFAOYSA-N 4-methylcyclohexane-1-carboxylic acid Chemical compound CC1CCC(C(O)=O)CC1 QTDXSEZXAPHVBI-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- ZVQOOHYFBIDMTQ-UHFFFAOYSA-N [methyl(oxido){1-[6-(trifluoromethyl)pyridin-3-yl]ethyl}-lambda(6)-sulfanylidene]cyanamide Chemical compound N#CN=S(C)(=O)C(C)C1=CC=C(C(F)(F)F)N=C1 ZVQOOHYFBIDMTQ-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- BFAKENXZKHGIGE-UHFFFAOYSA-N bis(2,3,5,6-tetrafluoro-4-iodophenyl)diazene Chemical compound FC1=C(C(=C(C(=C1F)I)F)F)N=NC1=C(C(=C(C(=C1F)F)I)F)F BFAKENXZKHGIGE-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/02—Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/59—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57226685A JPS59118750A (ja) | 1982-12-27 | 1982-12-27 | カルボン酸アミド化合物およびその誘導体 |
AU22531/83A AU2253183A (en) | 1982-12-27 | 1983-12-19 | Carboxylic acid amides and carboximides |
GB08333713A GB2133006B (en) | 1982-12-27 | 1983-12-19 | Bis (trifluoromethyl) aniline derivatives |
CA000443811A CA1202312A (en) | 1982-12-27 | 1983-12-20 | Carboxylic acid amides and their derivatives |
NL8304406A NL8304406A (nl) | 1982-12-27 | 1983-12-22 | Carbonzuuramiden en derivaten ervan, werkwijzen voor de bereiding ervan en farmaceutische preparaten, die deze verbindingen bevatten. |
SE8307119A SE8307119L (sv) | 1982-12-27 | 1983-12-22 | Karboxylsyraamider och derivat derav |
PH30020A PH19459A (en) | 1982-12-27 | 1983-12-22 | Carboxylic acid amides and their derivatives |
ZA839546A ZA839546B (en) | 1982-12-27 | 1983-12-22 | Carboxylic acid amides and their derivatives |
DK596083A DK596083A (da) | 1982-12-27 | 1983-12-23 | Carboxylsyreamidderivat, fremgangsmaade til fremstilling deraf samt laegemiddel indeholdende en saadan forbindelse |
HU834462A HU189799B (en) | 1982-12-27 | 1983-12-23 | Process for preparing carboxylic acid amides and derivatives thereof further pharmaceutical compositions containing such compounds |
DE19833346814 DE3346814A1 (de) | 1982-12-27 | 1983-12-23 | Carbonsaeureamidderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten |
IT24351/83A IT1170275B (it) | 1982-12-27 | 1983-12-23 | Ammidi di acidi carbossilici e loro derivati |
CH6912/83A CH656875A5 (de) | 1982-12-27 | 1983-12-23 | Amide von carbonsaeuren und ihre derivate. |
ES528409A ES528409A0 (es) | 1982-12-27 | 1983-12-26 | Un procedimiento para preparar compuestos de amida de acido carboxilico |
KR1019830006180A KR840007714A (ko) | 1982-12-27 | 1983-12-26 | 카르복실산 아마이드류의 제조방법 |
BE0/212130A BE898570A (fr) | 1982-12-27 | 1983-12-27 | Nouveaux amides et imides carboxyliques, procédés pour leur préparation et composition pharmaceutique les contenant. |
FR8320864A FR2538386B1 (fr) | 1982-12-27 | 1983-12-27 | Nouveaux amides et imides carboxyliques procedes pour leur preparation et composition pharmaceutique les contenant |
ES543810A ES8608486A1 (es) | 1982-12-27 | 1985-06-01 | Un procedimiento para preparar un compuesto de carboximida |
US06/803,526 US4661630A (en) | 1982-12-27 | 1985-12-02 | Carboxylic acid amides and their derivatives |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP57226685A JPS59118750A (ja) | 1982-12-27 | 1982-12-27 | カルボン酸アミド化合物およびその誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS59118750A JPS59118750A (ja) | 1984-07-09 |
JPH0136819B2 true JPH0136819B2 (US20030220297A1-20031127-C00074.png) | 1989-08-02 |
Family
ID=16849045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP57226685A Granted JPS59118750A (ja) | 1982-12-27 | 1982-12-27 | カルボン酸アミド化合物およびその誘導体 |
Country Status (18)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4057782A1 (en) | 2021-03-12 | 2022-09-14 | Atotech Deutschland GmbH & Co. KG | Method for increasing adhesion strength between copper and an organic material and reducing halo and wedge void formation by modifying the copper surface and/or by using heteroaromatic silane compounds |
EP4056285A1 (en) | 2021-03-12 | 2022-09-14 | Atotech Deutschland GmbH & Co. KG | Triazine silane compound and its usage as adhesion promotor |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59231057A (ja) * | 1983-06-14 | 1984-12-25 | Eisai Co Ltd | カルボン酸アミド化合物およびその誘導体 |
DE3334822A1 (de) * | 1983-09-26 | 1985-04-04 | Bayer Ag, 5090 Leverkusen | Neue flammschutzmittel, ihre herstellung und ihre verwendung zur flammfestausruestung von polycarbonaten |
EP1854798A3 (en) | 2000-09-19 | 2007-11-28 | Bristol-Myers Squibb Company | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
KR20090090406A (ko) * | 2000-12-18 | 2009-08-25 | 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 | 염증성 사이토카인 생산 유리 억제제 |
US20040087548A1 (en) | 2001-02-27 | 2004-05-06 | Salvati Mark E. | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
MXPA04000224A (es) | 2001-07-10 | 2005-07-25 | 4Sc Ag | Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos. |
DE10222895A1 (de) * | 2002-05-23 | 2003-12-11 | Bosch Gmbh Robert | Hochdruckspeicher für Kraftstoffeinspritzsysteme mit integriertem Druckregelventil |
CA2487891A1 (en) * | 2002-06-05 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Inhibitors against the activation of ap-1 and nfat |
CA2487900A1 (en) * | 2002-06-05 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Immunity-related protein kinase inhibitors |
EA008769B1 (ru) * | 2002-06-05 | 2007-08-31 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Лекарственное средство для лечения диабета |
EP1514544A4 (en) * | 2002-06-06 | 2009-01-07 | Inst Med Molecular Design Inc | HYPO-ALLERGENIC |
EA009051B1 (ru) * | 2002-06-06 | 2007-10-26 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | О-замещенные гидроксиарильные производные |
CA2489091A1 (en) * | 2002-06-10 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Inhibitors against activation of nf-kappab |
AU2003242108B2 (en) * | 2002-06-10 | 2008-09-11 | Institute Of Medicinal Molecular Design, Inc. | Medicament for treatment of cancer |
CN100490793C (zh) * | 2002-06-11 | 2009-05-27 | 株式会社医药分子设计研究所 | 神经变性疾病治疗药 |
KR20050074949A (ko) * | 2002-11-12 | 2005-07-19 | 엔오케이 가부시키가이샤 | 고무형상 탄성부품 |
US7365094B2 (en) | 2002-12-23 | 2008-04-29 | 4Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
WO2004056746A1 (en) * | 2002-12-23 | 2004-07-08 | 4Sc Ag | Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
EP1581478A1 (en) * | 2002-12-23 | 2005-10-05 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
US7247736B2 (en) * | 2002-12-23 | 2007-07-24 | 4Sc Ag | Method of identifying inhibitors of DHODH |
EP1541198A1 (en) * | 2003-12-05 | 2005-06-15 | 4Sc Ag | Cycloalkyl compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
EP2585054A1 (en) * | 2010-06-24 | 2013-05-01 | Allergan, Inc. | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
UA108760C2 (uk) | 2010-07-01 | 2015-06-10 | Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби | |
RS65563B1 (sr) | 2018-03-16 | 2024-06-28 | Immunic Ag | Novi polimorfi kalcijumove soli kao anti-inflamatorni, imunomodulatorni i anti-proliferativni agensi |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5379871A (en) * | 1976-12-22 | 1978-07-14 | Monsanto Co | Aromatic system acid compounds |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2794811A (en) * | 1954-06-03 | 1957-06-04 | Allied Chem & Dye Corp | Production of cis-cyclohexane-1, 2-dicarboxylic anhydride |
US2959599A (en) * | 1956-11-19 | 1960-11-08 | Allied Chem | Isomerization of cyclohexene-1, 2-dicarboxylic anhydrides |
US3085096A (en) * | 1961-05-31 | 1963-04-09 | Petro Tex Chem Corp | Preparation of cis-4-cyclohexene-1, 2-di-carboxylic acid anhydride |
US3507904A (en) * | 1966-04-01 | 1970-04-21 | Herbert Schwartz | Novel tetrahydrophthalamic acids and derivatives thereof |
CH489993A (de) * | 1967-12-19 | 1970-05-15 | Ciba Geigy | Das Pflanzenwachstum regulierendes und phytocides Mittel |
US3922158A (en) * | 1967-12-19 | 1975-11-25 | Ciba Geigy Ag | Method for inhibiting the growth of dicotyledonous plants |
US3549655A (en) * | 1967-12-21 | 1970-12-22 | Dow Chemical Co | N-(substituted phenyl) cyclobutanedicarboximides |
US3745170A (en) * | 1969-03-19 | 1973-07-10 | Sumitomo Chemical Co | Novel n-(3,5-dihalophenyl)-imide compounds |
FR2059977A1 (US20030220297A1-20031127-C00074.png) * | 1969-08-14 | 1971-06-11 | Socibre | |
US3825594A (en) * | 1970-01-20 | 1974-07-23 | Sandoz Ag | Bis(trifluoromethyl)benzamides |
US3654302A (en) * | 1970-01-30 | 1972-04-04 | Herbert Schwartz | Tetrahydrophthalanils |
US3987056A (en) * | 1973-05-07 | 1976-10-19 | Phillips Petroleum Company | Disproportionation of n-aryl-1,2,3,6-tetrahydrophthalimides |
US4002460A (en) * | 1974-03-13 | 1977-01-11 | Stauffer Chemical Company | Triazine-antidote compositions and methods of use for cotton |
US4025505A (en) * | 1975-02-04 | 1977-05-24 | Ciba-Geigy Corporation | Aromatic dicarboxamides |
CH615912A5 (US20030220297A1-20031127-C00074.png) * | 1975-06-18 | 1980-02-29 | Ciba Geigy Ag | |
FR2369252B1 (fr) * | 1976-10-29 | 1979-02-23 | Inst Nat Rech Chimique | Composes a,a-difluoroalkylbenzenes substitues et leur fabricationÿ |
JPS5524127A (en) * | 1978-08-08 | 1980-02-21 | Morishita Seiyaku Kk | 3,6-endomethylene-delta4-1,2,3,6-tetrahydrophtalimide derivative |
EP0017994A3 (de) * | 1979-04-20 | 1981-01-14 | Ciba-Geigy Ag | Cyclobutandicarbonsäureimide, Verfahren zu deren Herstellung und deren Verwendung als Fungizid; Zwischenprodukte |
JPS56169669A (en) * | 1980-05-30 | 1981-12-26 | Takeda Chem Ind Ltd | Hexahydroisoindole derivative, its preparation and herbicide |
JPS59231057A (ja) * | 1983-06-14 | 1984-12-25 | Eisai Co Ltd | カルボン酸アミド化合物およびその誘導体 |
-
1982
- 1982-12-27 JP JP57226685A patent/JPS59118750A/ja active Granted
-
1983
- 1983-12-19 GB GB08333713A patent/GB2133006B/en not_active Expired
- 1983-12-19 AU AU22531/83A patent/AU2253183A/en not_active Abandoned
- 1983-12-20 CA CA000443811A patent/CA1202312A/en not_active Expired
- 1983-12-22 ZA ZA839546A patent/ZA839546B/xx unknown
- 1983-12-22 SE SE8307119A patent/SE8307119L/xx not_active Application Discontinuation
- 1983-12-22 PH PH30020A patent/PH19459A/en unknown
- 1983-12-22 NL NL8304406A patent/NL8304406A/nl not_active Application Discontinuation
- 1983-12-23 DE DE19833346814 patent/DE3346814A1/de not_active Withdrawn
- 1983-12-23 CH CH6912/83A patent/CH656875A5/de not_active IP Right Cessation
- 1983-12-23 IT IT24351/83A patent/IT1170275B/it active
- 1983-12-23 HU HU834462A patent/HU189799B/hu unknown
- 1983-12-23 DK DK596083A patent/DK596083A/da not_active Application Discontinuation
- 1983-12-26 KR KR1019830006180A patent/KR840007714A/ko not_active Application Discontinuation
- 1983-12-26 ES ES528409A patent/ES528409A0/es active Granted
- 1983-12-27 BE BE0/212130A patent/BE898570A/fr not_active IP Right Cessation
- 1983-12-27 FR FR8320864A patent/FR2538386B1/fr not_active Expired
-
1985
- 1985-06-01 ES ES543810A patent/ES8608486A1/es not_active Expired
- 1985-12-02 US US06/803,526 patent/US4661630A/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5379871A (en) * | 1976-12-22 | 1978-07-14 | Monsanto Co | Aromatic system acid compounds |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4057782A1 (en) | 2021-03-12 | 2022-09-14 | Atotech Deutschland GmbH & Co. KG | Method for increasing adhesion strength between copper and an organic material and reducing halo and wedge void formation by modifying the copper surface and/or by using heteroaromatic silane compounds |
EP4056285A1 (en) | 2021-03-12 | 2022-09-14 | Atotech Deutschland GmbH & Co. KG | Triazine silane compound and its usage as adhesion promotor |
WO2022189644A1 (en) | 2021-03-12 | 2022-09-15 | Atotech Deutschland GmbH & Co. KG | Method for increasing adhesion strength between copper and an organic material and reducing halo and wedge void formation by modifying the copper surface and/or by using heteroaromatic silane compounds |
WO2022189646A1 (en) | 2021-03-12 | 2022-09-15 | Atotech Deutschland GmbH & Co. KG | Triazine silane compound and its usage as adhesion promotor |
Also Published As
Publication number | Publication date |
---|---|
SE8307119L (sv) | 1984-06-28 |
FR2538386B1 (fr) | 1986-04-18 |
ES8608486A1 (es) | 1986-06-16 |
CH656875A5 (de) | 1986-07-31 |
BE898570A (fr) | 1984-06-27 |
ES543810A0 (es) | 1986-06-16 |
GB8333713D0 (en) | 1984-01-25 |
GB2133006B (en) | 1986-10-22 |
DK596083D0 (da) | 1983-12-23 |
HU189799B (en) | 1986-07-28 |
GB2133006A (en) | 1984-07-18 |
DE3346814A1 (de) | 1984-06-28 |
PH19459A (en) | 1986-04-18 |
ZA839546B (en) | 1984-08-29 |
IT1170275B (it) | 1987-06-03 |
ES8601859A1 (es) | 1985-11-01 |
AU2253183A (en) | 1984-07-05 |
FR2538386A1 (fr) | 1984-06-29 |
US4661630A (en) | 1987-04-28 |
ES528409A0 (es) | 1985-11-01 |
DK596083A (da) | 1984-06-28 |
NL8304406A (nl) | 1984-07-16 |
CA1202312A (en) | 1986-03-25 |
JPS59118750A (ja) | 1984-07-09 |
IT8324351A0 (it) | 1983-12-23 |
SE8307119D0 (sv) | 1983-12-22 |
KR840007714A (ko) | 1984-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH0136819B2 (US20030220297A1-20031127-C00074.png) | ||
EP2186792B1 (en) | 2-(a-hydroxypentyl) benzoate and its preparation and use | |
EP0415850A1 (fr) | Sels de métaux bivalents de l'acide N, N-di(carboxyméthyl)amino-2 cyano-3 carboxyméthyl-4 carboxy-5 thiophène,leur procédé de préparation et les compositions pharmaceutiques les renfermant | |
IE47798B1 (en) | Substituted ortho-anisamides,methods of preparing them,compositions containing them and their application as psychotropic agents | |
EP0025192A2 (de) | Substituierte Oxirancarbonsäuren, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende Arzneimittel | |
DE3411993A1 (de) | Substituierte benzopyrane, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimittel | |
CN115304593A (zh) | 苯并异噻唑化合物及其药物组合物和应用 | |
HU196354B (en) | Process for producing compounds with antiprotozoal effect and pharmaceutical compositions comprising them as active ingredient | |
DE69108408T2 (de) | 4,5-dihydroxy und 4,5,8-trihydroxy-9,10-dioxo-2-anthracencarbonsäure-dikohlensäureester und urethane mit therapeutischer wirkung. | |
US3843796A (en) | Antihypertensive agents | |
WO2017129061A1 (zh) | 取代桂皮酰胺衍生物在制备抗焦虑药物中的应用 | |
AT391320B (de) | Piperazincarbonsaeure, ihre herstellung und diese enthaltende arzneimittel | |
JPH03503162A (ja) | 化学療法における毒性特性の改良 | |
JPS6117574A (ja) | カルシウム拮抗活性のある1‐〔ビス‐(4‐ルオロフエニル)‐メチル〕‐4‐(3‐フエニル‐2‐プロペニル)‐ヘキサヒドロ‐1h‐1,4‐ジアゼピンとその製法及びそれを含有する医薬組成物 | |
BE882315A (fr) | Composes de 6-aryl pyrimidine, leur preparation et leur utilisation | |
KR102227100B1 (ko) | 도네페질 에테르 팔미테이트 또는 이의 약제학적으로 허용가능한 염 | |
CN112457291B (zh) | 苯并硫代吡喃酮类化合物的盐及其制备方法和用途 | |
CH651294A5 (fr) | Acides amino-2-halogenobenzoyl-3-methylphenylacetiques et leurs esters et sels utiles comme medicaments anti-inflammatoires et analgesiques. | |
JP2567593B2 (ja) | イミダゾリジントリオン誘導体及び該化合物を有効成分として含有するアレルギ−性疾患治療剤 | |
KR20230148177A (ko) | N-((r)-2,3-디하이드록시프로폭시)-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤즈아미드의 본질적으로 순수한 형태 iv의 조성물 및 이의 용도 | |
JP3032053B2 (ja) | ウリジン誘導体及びこれを含有する医薬 | |
US3294638A (en) | Method and compositions employing 2-alkyl-3-piperidinopyrazines | |
US4596826A (en) | Carboxylic acid amide compounds and their derivatives | |
US4024259A (en) | 3-Anilino-2,4-diazabicyclo[3.2.1]octenes | |
WO2003099269A1 (en) | Cinnamic acid dimers, their preparation and the use thereof for treating neurodegenerative disease |